Skip to main content
Premium Trial:

Request an Annual Quote

TNO, Mitsubishi Pharma Enter siRNA Target Validation Pact

NEW YORK, Sept. 6 (GenomeWeb News) - Dutch biotech TNO and Mitsubishi Pharma of Japan have entered into a technology development collaboration for siRNA-based target validation studies.


Under the terms of the agreement, TNO will use its siRNA knockdown technology and disease models to further characterize a set of Mitsubishi's proprietary disease targets.


Financial terms of the agreement were not disclosed.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.